SCYNEXIS, Inc.

SCYNEXIS, Inc.

Biotechnology Research

Jersey City, New Jersey 6,054 followers

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens

About us

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Jersey City, New Jersey
Type
Public Company
Founded
2000
Specialties
Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease

Locations

Employees at SCYNEXIS, Inc.

Updates

Similar pages

Browse jobs

Funding

SCYNEXIS, Inc. 7 total rounds

Last Round

Post IPO equity

US$ 45.0M

See more info on crunchbase